Santen Pharmaceutical has issued its integrated report “Santen Report 2026” for the fiscal year ending March 2026 in Japanese and English, introducing its initiatives aimed at sustainable growth and value creation under the 2025-2029 fiscal-year medium-term management plan.
Santen Pharmaceutical has issued the Japanese and English versions of its integrated report “Santen Report 2026” for the fiscal year ending March 2026. Based on the 2025-2029 fiscal-year medium-term management plan, the report sets out the company’s initiatives for long-term value creation and growth.
The report introduces the company’s efforts to address unmet needs by working with patients, healthcare professionals and the ophthalmology community amid changes in the ophthalmic market, as well as its business and financial strategies for sustainable growth.
The report is available on Santen Pharmaceutical’s corporate website, where both the Japanese and English versions can be viewed.